## **IN THE CLAIMS**

Please replace the claims as filed with the claims set forth below. This listing of claims will replace all prior versions, and listings, of claims in the application:

## **CLAIMS:**

- 1. (Original) A method for the treatment of sepsis, inflammation or infection comprising providing to a recipient a physiologically effective amount of a pharmaceutical composition comprising a molecule that targets SR-BI/CLA-1.
- 2. (Withdrawn) The method of claim 1, wherein said method provides a treatment for sepsis.
- 3. (Original) The method of claim 1, wherein said method provides a treatment for inflammation.
- 4. (Withdrawn) The method of claim 1, wherein said method provides a treatment for infection.
- 5. (Original) The method of claim 1, wherein said molecule is a peptide or is a peptide composition having a peptide portion.
- 6. (Original) The method of claim 5, wherein said peptide or peptide composition effects LPS-uptake or LPS-stimulated cytokine production.
- 7. (Original) The method of claim 6, wherein said molecule is a peptide that binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- 8. (Original) The method of claim 7, wherein said peptide is composed solely of L-amino acid residues.

- 9. (Original) The method of claim 7, wherein said peptide is composed solely of D-amino acid residues.
- 10. (Original) The method of claim 5, wherein said molecule is a peptide composition and wherein said peptide portion of said peptide composition binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- 11. (Original) The method of claim 10, wherein said peptide portion of said peptide composition is composed solely of L-amino acid residues.
- 12. (Original) The method of claim 10, wherein said peptide portion of said peptide composition is composed solely of D-amino acid residues.
- 13. (Original) The method of claim 1, wherein said molecule is selected from the group consisting of a cholesterol absorption inhibitor, a viral fusion inhibitor, a negatively charged lipid that binds to CLA-1 with a Kd lower than  $10^{-7}$  M; an anti-SR-BI/CLA-1 antibody, of fragment thereof that binds SR-BI/CLA-1, and a chemical substance that binds to SR-BI/CLA-1 with a Kd lower than  $10^{-7}$  M.
- 14. (Withdrawn) A pharmaceutical composition for the treatment of sepsis, inflammation or infection comprising providing to a recipient a physiologically effective amount of a pharmaceutical composition comprising:(A) a molecule that targets SR-BI/CLA-1; and(B) an auxiliary agent, excipient, or uptake facilitating agent.
- 15. (Withdrawn) The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a treatment for sepsis.
- 16. (Withdrawn) The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a treatment inflammation.

- 17. (Withdrawn) The pharmaceutical composition of claim 14, wherein said physiologically effective amount is effective for providing a treatment infection.
- 18. (Withdrawn) The pharmaceutical composition of claim 14, wherein said molecule is a peptide or is a peptide composition having a peptide portion.
- 19. (Withdrawn) The pharmaceutical composition of claim 18, wherein said peptide or peptide composition effects LPS-uptake or LPS-stimulated cytokine production.
- 20. (Withdrawn) The pharmaceutical composition of claim 18, wherein said molecule is a peptide that binds to an anionic amphipathic .alpha.-helix of SR-BI/CLA-1.
- 21. (Withdrawn) The pharmaceutical composition of claim 19, wherein said peptide is composed solely of L-amino acid residues.
- 22. (Withdrawn) The pharmaceutical composition of claim 19, wherein said peptide is composed solely of D-amino acid residues.
- 23. (Withdrawn) The pharmaceutical composition of claim 18, wherein said molecule is a peptide composition and wherein said peptide portion of said peptide composition binds to an anionic amphipathic  $\alpha$ -helix of SR-BI/CLA-1.
- 24. (Withdrawn) The pharmaceutical composition of claim 23, wherein said peptide portion of said peptide composition is composed solely of L-amino acid residues.
- 25. (Withdrawn) The pharmaceutical composition of claim 23, wherein said peptide portion of said peptide composition is composed solely of D-amino acid residues.
- 26. (Withdrawn) The pharmaceutical composition of claim 14, wherein said molecule is selected from the group consisting of a cholesterol absorption inhibitor, a viral fusion inhibitor, a negatively charged lipid that binds to CLA-1 with a Kd lower than 10<sup>-7</sup> M; an anti-SR-BI/CLA-1

antibody, of fragment thereof that binds SR-BI/CLA-1, and a chemical substance that binds to SR-BI/CLA-1 with a Kd lower than  $10^{-7}$  M.